Lysine

Lysine

SCHEMBL1675274

C[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O.NCCCC[C@H](N)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.51
DPP7 Q9UHL4 7/20 0.38
DPP4 P27487 4/20 0.38
DPP8 Q6V1X1 3/20 0.38
DPP9 Q86TI2 2/20 0.38
FAP Q12884 1/20 0.36
ARG1 P05089 3/20 0.35
ARG2 P78540 3/20 0.35
NOS3 P29474 2/20 0.35
NOS1 P29475 2/20 0.35
NOS2 P35228 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL5575951 1.00 GSR (0.51) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL29069496 1.00 GSR (0.51) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL18263286 0.96 GSR (0.48) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL18259132 0.96 GSR (0.48) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL17728306 0.95 GSR (0.47) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL23834597 0.95 GSR (0.57) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL5227175 0.95 GSR (0.57) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL4296375 0.95 GSR (0.57) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL1696608 0.95 GSR (0.57) GSRDPP7DPP4DPP8DPP9
Lysine SCHEMBL11660661 0.95 GSR (0.57) GSRDPP7DPP4DPP8DPP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458197-B2 Elastin digest compositions and methods utilizing same HUMAN MATRIX SCIENCES, LLC (US) 2016-10-04 US disclosed
US-20150110755-A1 ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME NULASTIN, INC. 2015-04-23 US disclosed
US-9006170-B2 Compositions for elastogenesis and connective tissue treatment HUMAN MATRIX SCIENCES, LLC (US) 2015-04-14 US disclosed
US-20150004184-A1 ELASTIN DIGEST COMPOSITIONS AND METHODS UTILIZING SAME NULASTIN, INC. 2015-01-01 US disclosed
US-8871707-B2 Elastin producing fibroblast formulations and methods of using the same HUMAN MATRIX SCIENCES, LLC (US) 2014-10-28 US disclosed
US-8828927-B2 Elastin digest compositions and methods utilizing same HUMAN MATRIX SCIENCES, LLC (US) 2014-09-09 US disclosed
US-20130295122-A1 ELASTIN DIGEST COMPOSITIONS AND METHODS UTILIZING SAME NULASTIN, INC. 2013-11-07 US disclosed
US-8461113-B2 Elastin digest compositions and methods utilizing same HUMAN MATRIX SCIENCES, LLC (US) 2013-06-11 US disclosed
US-20110081322-A1 ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME NULASTIN, INC. 2011-04-07 US disclosed
US-7803522-B2 Elastin producing fibroblast formulations and methods of using the same HUMAN MATRIX SCIENCES, LLC (US) 2010-09-28 US disclosed
US-7666829-B2 contains manganese chloride, manganese sulfate or manganese nitrate and ferric ammonium citrate or ferric chloride, for treating skin disorders; stimulating production of insoluble elastin, or deposition of collagen, fibroblasts; improve the appearance of scar; wrinkle resistance HUMAN MATRIX SCIENCES, LLC (US) 2010-02-23 US disclosed
US-20090281044-A1 ELASTIN DIGEST COMPOSITIONS AND METHODS UTILIZING SAME NULASTIN, INC. 2009-11-12 US disclosed
US-7560430-B2 To stimulate the endogenous production of Elastin or appear to enhance the elasticity of the skin HUMAN MATRIX SCIENCES, LLC (US) 2009-07-14 US disclosed
US-20080050346-A1 Elastin producing fibroblast formulations and methods of using the same NULASTIN, INC. 2008-02-28 US disclosed